Company Filing History:
Years Active: 2021
Title: Innovations by Jean-Philippe Bürckert
Introduction
Jean-Philippe Bürckert is a notable inventor based in Belmont, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for viral infections. With a total of 5 patents to his name, Bürckert's work is at the forefront of medical innovation.
Latest Patents
One of Bürckert's latest patents is focused on Anti-SARS-CoV-2 antibodies derived from 6nb6. This disclosure provides antibodies and antigen-binding fragments that can be administered to individuals infected or suspected of being infected with the virus. These antibodies are capable of treating or curing the virus and may provide protection for several weeks. Additionally, they can be used to diagnose a SARS-CoV-2 infection. Another significant patent involves Anti-SARS-CoV-2 antibodies derived from CR3022, which also offers similar therapeutic and diagnostic capabilities.
Career Highlights
Bürckert is currently associated with Centivax, Inc., where he continues to innovate in the field of antibody development. His work is crucial in addressing viral infections and enhancing treatment options for patients.
Collaborations
Bürckert collaborates with notable colleagues such as Jacob Glanville and Shahrad Daraeikia, contributing to a dynamic research environment focused on advancing medical science.
Conclusion
Jean-Philippe Bürckert's contributions to the field of biotechnology, particularly through his innovative patents, highlight his role as a leading inventor in the fight against viral infections. His work continues to pave the way for new therapeutic solutions.